Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer With Osimertinib Third-line Rechallenge
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This phase II single-armed study will examine the clinical utility of retreating patients
with osimertinib, in the third-line, following first-line treatment with osimertinib and
second-line treatment with platinum and pemetrexed chemotherapy. The current standard of care
for first-line Epidermal Growth Factor Receptor (EGFR) mutated Advanced Non-Small Cell Lung
Cancer (aNSCLC) is osimertinib, followed by cytotoxic chemotherapy.
The repeat of osimertinib following previous treatment failure is investigational, although
supported by scientific rationale. The dosing and scheduling of osimertinib follows its use
in approved settings. The investigators examine its tolerability and efficacy in this setting
to ensure osimertinib is a safe third-line option for patients with Epidermal Growth Factor
Receptor mutated (EGFR+) Advanced Non-Small Cell Lung Cancer(aNSCLC).